Best Oncology Companies in Netherlands
The 90 best Oncology companies in Netherlands in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: VectoryTx.
Tracking the best Oncology companies in Netherlands by disclosed equity funding, this directory covers 90 ventures with a combined $866M raised, ranked by capital momentum. The global oncology market sits at $250.9B in 2025 and is forecast to hit $668.3B by 2034 at an 11.5% CAGR, and the Dutch cohort is staking out real ground inside that expansion. VectoryTx leads the pack at $176M raised. Tagworks Pharmaceuticals follows at $65M. Avidicure at $50M. Those three alone account for the bulk of disclosed capital, while ScreenPoint and Sensius represent the leaner, earlier-stage bets that keep the pipeline credible.
So what's actually moving the needle here? Hot themes this quarter are cancer biomarkers, angiogenesis inhibitors, and counseling oncology infrastructure, which tells you the Dutch ecosystem isn't just chasing blockbuster therapeutics. It's building the diagnostic and support layer too. AI's expanding role in oncology genetics is reshaping how biomarker discovery gets done, and globally, precision medicine's momentum around ADCs and targeted therapies is accelerating the demand context these companies are building into. Cost-containment policies remain the structural friction you can't ignore, but I'd argue the funding concentration here suggests investors are betting the science outpaces the reimbursement headwinds.
- Oncology Market Is Encouraged to Reach USD 646.33 Billion by 2032
- Oncology R&D: emerging therapies and new challenges
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Oncology companies in Netherlands
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | VectoryTx Developer of therapeutics for neurodegenerative and muscular disorder | $176M | 31 mo ago | 78 | Sander Van Deventer Chief Executive Officer | Cart FunctionalitySquarespace CommerceSquarespace+16 | Top 10M | — | 3 job openings |
| 2 | Merus Developer of antibody-based drugs for cancer treatment | $156M | 90 mo ago | 221 | — | WordPressApple iCloud MailMicrosoft 365+22 | Top 5M | 1,027 patents Bispecific antibody therapeutics targeting cancer and immune checkpoints for oncology applications. | — |
| 3 | LAVA therapeutics Developer of novel gamma delta T-cell engagers to treat cancer | $102M | 69 mo ago | 15 | Erik van den Berg Co-Founder | DrupalApple iCloud MailMicrosoft 365+20 | Top 50M | 134 patents Multispecific antibody therapeutics linking gamma‑delta TCRs to tumor antigens | — |
| 4 | Tagworks Pharmaceuticals Developer of antibody-drug-conjugates for cancer treatment | $65M | 36 mo ago | 13 | Zach Taylor Co-Founder | WordPressMySQLPHP+22 | Top 50M | 73 patents Patents concentrated in health & consumer products | — |
| 5 | Avidicure Developer of immunotherapies for cancer therapeutics | $50M | 13 mo ago | — | Govert Schouten Co-Founder | WordPressMySQLPHP+10 | Top 50M | 8 patents Engineered cytokine/antibody fusion proteins for NK‑cell cancer immunotherapy | — |
| 6 | ISA Pharmaceuticals Developer of therapeutic vaccines for cancer and infectious diseases | $41M | 59 mo ago | 44 | — | — | — | 90 patents Peptide-based cancer vaccines and immunogenic formulations combined with PD‑1 inhibition | — |
| 7 | Anavo Therapeutics Developer of drugs for cancer treatment | $33M | 37 mo ago | 10 | Birgit Zech CEO | Squarespace CommerceSquarespaceVimeo+12 | Top 50M | 3 patents Small-molecule WIP1 phosphatase inhibitors for cancer therapy | 1 job opening |
| 8 | ScreenPoint Developer of artificial intelligence software for analyzing breast imaging mammograms | $33M | 2 mo ago | 58 | Michael Brady Co-Founder & Chairman | WordPressMySQLPHP+21 | Top 10M | — | — |
| 9 | Kiadis Pharma Developer of cell-based immunotherapy products for the treatment of blood cancers | $33M | 68 mo ago | 103 | — | — | — | 29 patents Manufacturing expanded NK cell therapies and validating flow cytometry analytical methods. | — |
| 10 | InteRNA Technologies Discovering and developing microRNA (miRNA)-based therapeutics for oncology | $33M | 64 mo ago | 13 | — | — | — | 20 patents Patents concentrated in chemistry & materials | — |
| 11 | Flindr Developer of precision oncology treatments | $21M | 25 mo ago | — | Christian Blank Co-Founder | WordPressPleskApple iCloud Mail+27 | Top 50M | — | — |
| 12 | Cristal Therapeutics Provides nanomedicines based ON CriPec platform for cancer and inflammation disorder | $21M | 68 mo ago | 6 | Cristianne Rijcken Founder and CSO | — | — | — | 2 launchs |
| 13 | Acerta Pharma Small molecules for blood cancer and autoimmune diseases. | $13M | 149 mo ago | 150 | — | Adobe Experience ManagerJavaAmazon ALB+15 | Top 10M | 337 patents Solid-state forms and formulations of BTK/BCL-2 inhibitor small‑molecule drugs | 1 job opening |
| 14 | ORCA Therapeutics Provider of virus mediated immunotherapy for cancer | $9M | 121 mo ago | 4 | — | — | — | 9 patents Patents concentrated in chemistry & materials | — |
| 15 | InnoSIGN Developer of mRNA-based diagnosis platform for precision medicine | $8M | 51 mo ago | 16 | Paul Van De Wiel Chief Operating Officer | Co-Founder | — | — | 50 patents Computational biomarkers for signaling pathway activity in oncology and infectious disease | — |
| 16 | Gadeta T Cell based cancer therapies based on gamma delta (γδ) T cell receptors | $8M | 66 mo ago | 31 | — | — | — | 61 patents Engineered gamma‑delta T‑cell receptors and cell therapies for cancer and infection | — |
| 17 | Self-screen Provider of self-screening solutions for cervical cancer | $8M | 77 mo ago | — | — | — | — | 95 patents Epigenetic DNA‑methylation diagnostic assays for HPV‑related gynecological and anogenital cancers | — |
| 18 | Sensius Developer of a hyperthermia system for cancer treatment. | $8M | 12 mo ago | — | Paul Den Biggelaar Co-Founder & CEO | — | — | — | — |
| 19 | Scenic Biotech Developer of therapeutics for cancer and rare genetic diseases | $7M | 51 mo ago | 48 | Thijn Brummelkamp Founder & MD | WordPressPleskMySQL+17 | Top 50M | 10 patents Small‑molecule inhibitors of lysosomal enzymes (PLA2G15, ABHD18, GALK1) for disease therapy | — |
| 20 | DCprime Developer of immunotherapeutic solutions for treating cancer | $7M | 124 mo ago | 25 | — | — | — | 50 patents Novel dendritic cell-based cancer vaccines and tumor‑independent antigen immunotherapies | — |
| 21 | Glycostem Therapeutics Developer of allogeneic cellular immunotherapy for leukemia, lymphoma and solid tumors | $6M | 81 mo ago | 38 | — | DrupalApple iCloud MailPHP+12 | Top 50M | 30 patents Engineered NK cell immunotherapies and manufacturing methods for cancer treatment | — |
| 22 | CimCure Developer of immune therapy for treating solid tumors | $5M | 48 mo ago | 8 | Diederik Engbersen Chief Executive Officer | — | — | — | — |
| 23 | Pan Cancer T Provider of TCR T-cell therapeutics for the treatment of cancer | $5M | 6 mo ago | 8 | Reno Debets Founder | WordPressMySQLPHP+13 | Top 50M | — | — |
| 24 | Pleco Therapeutics Developer of therapeutics to treat cancer | $4M | 45 mo ago | 7 | Rudi Jansen Chief Business Officer - Chairman of the non-Executive Board and co-Founder at Pleco Therapeutics BV | — | — | 11 patents Chelation-based cancer therapies and heavy‑metal accumulation models for drug testing | — |
| 25 | Apo-T Dutch, private, biopharma company developing antibody-drug conjugates and apoptosis-inducers for cancer… | $3M | 146 mo ago | — | dr Willemsen Founder | — | — | 67 patents Bispecific immunotherapeutic agents directing immune cells to tumor antigens | — |
| 26 | Caelus Health Developer of microbiota-based products to address cardiometabolic disorders | $3M | 112 mo ago | 5 | Max Nieuwdorp Co-Founder | — | — | — | — |
| 27 | Cleara Developer of biomarkers and therapies to treat cancer and aging diseases | $2M | 44 mo ago | 10 | Marco Demaria Co-Founder | WordPressMySQLPHP+12 | Top 50M | — | — |
| 28 | SkylineDX Provider of gene expression profiling tests for personalized medicine | $2M | 54 mo ago | 61 | Dharminder Chahal CEO | WordPressMySQLPHP+19 | Top 10M | 27 patents Predictive gene expression biomarkers for melanoma metastasis and treatment response | — |
| 29 | OncoLize Developer of injectable drug depots to treat tumors | $2M | 38 mo ago | 5 | Mike De Leeuw Chief Executive Officer & Founder | — | — | — | — |
| 30 | VitroScan Provider of a diagnostic platform for precision treatments for cancer patients | $901K | 18 mo ago | 6 | Willemijn Vader Managing Director | — | — | 8 patents Ex vivo tumor organoid platforms for immune response measurement and personalized immunotherapy | 1 partnership |
| 31 | PA Imaging R&D Provider of screening and diagnostic mammograms | $859K | 113 mo ago | 7 | Paul Nederkoorn Co-Founder & CEO | — | — | — | — |
| 32 | Amphera Developing dendritic cell immunotherapies for treating malignant mesothelioma and other cancers | $538K | 125 mo ago | 4 | Rob Meijer CEO | — | — | 27 patents Cancer immunotherapy vaccines using dendritic cells loaded with tumor-derived lysates | — |
| 33 | Hercules Developer of Aryl Hydrocarbon Receptor inhibiting drug for Triple Negative Breast Cancer treatment | $354K | 70 mo ago | 2 | — | — | — | 20 patents Patents concentrated in textiles | — |
| 34 | Imuno Therapeutics Developer of drug discovery and precision therapy platform for oncology | $340K | 55 mo ago | 5 | Jan Verhoef Founder | — | — | — | — |
| 35 | CiMaas Developer of immunotherapeutics for cancer treatment | $313K | 77 mo ago | 9 | Wilfred V Germeraad Co-Founder & COO | — | — | 7 patents Manufacturing and preparation of mitotically suppressed and mature dendritic cells for cell therapies | 1 partnership |
| 36 | BIMINI Biotech Developer of therapeutics for the treatment of cancer | $238K | 17 mo ago | 4 | Ger Strous Co-Founder | — | — | — | 1 expansion |
| 37 | Dualtpharma Dutch, preclinical pharma developing combination therapies for solid tumors. | $137K | 105 mo ago | — | Patrick De Boer CEO | — | — | — | — |
| 38 | ScarTec Therapeutics Developer of therapeutics for the treatment of cancer | $112K | 84 mo ago | — | Jai Prakash Founder & Managing Director | — | — | — | — |
| 39 | SurGuide Developer of device for removing tumour from oral cancer | $112K | 84 mo ago | — | Gerwin Puppels Co-Founder & CTO | — | — | — | — |
| 40 | Frame Therapeutics Developer of immunotherapies for cancer treatment | $111K | 76 mo ago | 13 | Bob Lowenberg Co-Founder | — | — | — | — |
| 41 | Cytofind Developer of diagnostic test to detect circulating tumor cells | $109K | 113 mo ago | — | Wilhelm Huck ex-Co-Founder | — | — | — | — |
Top 12 Oncology companies in Netherlands
#1
Series C · Nijmegen, Gelderland · founded 2014 · 58 employees$33Mraised▾
Developer of artificial intelligence software for analyzing breast imaging mammograms. This technology integrates with existing medical imaging hardware to assist radiologists in detecting cancer. The software provides automated analysis of breast density and compares current images against previous examinations to identify potential abnormalities. It functions across various imaging systems to support clinical workflows in diagnostic environments.
- Apr 2026Series C$14M
- Apr 2026Grant (prize money)$2M
- Jul 2021Series C$28M
- May 2018Series B$5M
#2
Seed · Amsterdam, North Holland · founded 2022$50Mraised▾
Developer of immunotherapies for cancer therapeutics. It offers AVC-Boosters supercharged antibodies that boost the number and function of NK cells at the tumor, cause activation of the full immune system and provide broad TME-resistant anti-tumor responses.
- Apr 2025Seed$50M
#3
Series A · Rotterdam, South Holland · founded 2020 · 8 employees$4.6Mraised▾
Provider of TCR T-cell therapeutics for the treatment of cancer. The company uses the adoptive T cell therapies for treating pan-cancer. The company pipeline product includes MAGE-C2/HLA-A2 TCR and epigenetic drugs which can be used in the treatment of melanoma and head-and-neck carcinoma. The company also offers Pan-Cancer T’s platforms which include a dose-escalation of TCR T cells.
- Dec 2025Series A$5.8M
- Dec 2025Conventional Debt$5.8M
- Jul 2024Seed$4.6M
- Oct 2021Seed—
#4
Series B · Rotterdam, South Holland · founded 2015$7.5Mraised▾
{}
- Jun 2025Series B$17.2M
- Feb 2023Series A$7.2M
- 2022Grant (prize money)$2.8M
- Jan 2022Grant (prize money)$2.8M
#5
Series A · Amsterdam, North Holland · founded 2020 · 78 employees$175.6Mraised▾
Developer of therapeutics for neurodegenerative and muscular disorders. The products contain next-generation viral vectors that target specific cell types and subcellular compartments while evading the host immune response. The company is developing therapeutics based on an AAV gene therapy platform, antibody, and RNA-targeted degradation technologies.
- Nov 2023Series A$138M
- Jun 2021Seed$37.6M
#6
Series A · Nijmegen, Gelderland · founded 2011 · 13 employees$65Mraised▾
Developer of antibody-drug-conjugates for cancer treatment. It offers a lead product TGW101 that targets TAG72, a non-internalizing clinically validated pan-carcinoma target, present in several solid tumors. It also offersolid-tumor-targeted ADCs as well as radiopharmaceuticals including a HER2-targeted radioimmunotherapeutic.
- Jun 2023Series A$65M
- Mar 2023Grant (prize money)$477.5K
- Mar 2018Grant (prize money)$313.3K
- Jan 2016Grant (prize money)$1.7M
#7
Series A · Oss, North Brabant · founded 2020$21.4Mraised▾
Developer of precision oncology treatments. It offers small molecule inhibitors for cancer therapy to restore impaired immune responses in cancer patients by identifying and validating new therapeutic targets in both cancer and immune cell. It utillises ImmunoGram Drug Discovery Engine which involves reverse-translating the heterogeneity in tumor-specific and host-specific factors, into lab-based biological models to screen for and select the most important drug targets involved in patient clinical response.
- Apr 2024Series A$21.4M
- 2021Seed—
#8
Seed · Leiden, South Holland · founded 2020 · 10 employees$33.3Mraised▾
Developer of drugs for cancer treatment. The company is developing small molecule modulators of phosphatase and kinase activity that will help in cancer treatment.
- May 2023Seed$9.3M
- Apr 2021Seed$24M
#9
Acquired · Utrecht, Utrecht · founded 2003 · 221 employees$156.2Mraised▾
Developer of antibody-based drugs for cancer treatment. The company develops products using bispecific antibody engineering and advanced screening technologies that engage the power of the immune system to kill cancer cells. Its products include Zenocutuzomab, Petosemtamab, and MCLA-145 for lung, pancreatic and other cancers.
- Dec 2018Post IPO$15M
- Feb 2018Post IPO$55.8M
- Jan 2017Post IPO$80M
- Nov 2016Grant (prize money)—
#10
Seed · Leiden, South Holland · founded 2016 · 6 employees$901.3Kraised▾
Provider of a diagnostic platform for precision treatments for cancer patients. The company offers a 3D drug response platform that helps in predicting the drug reactions on the tumor cultures for drug optimization solutions. The platform gives insights by a systematic approach for measuring drug activity via advanced imaging technology and drug response analysis for better clinical outcomes.
- Dec 2024Grant (prize money)$2M
- Apr 2019Seed$901.3K
#11
Acquired · s Hertogenbosch, North Brabant · founded 2016 · 15 employees$101.8Mraised▾
LAVA therapeutics is a developer of novel gamma delta T-cell engagers to treat cancer. The company has developed Vγ9Vδ2 (gamma delta) T-cell receptor-based immuno-oncology assets for the treatment of tumours. The T-cell receptor of Vγ9Vδ2 T-cells can help in the development of adaptive immune responses and also in developing proprietary bispecific Vγ9Vδ2 T-cell engagers for selected tumour targets, which can bind to both tumour cells and the gamma delta T-cells.
- Sep 2020Series C$83M
- Jul 2020Series A—
- May 2018Series A$18.8M
#12
Series B · Leiden, South Holland · founded 2004 · 44 employees$40.5Mraised▾
Developer of therapeutic vaccines for cancer and infectious diseases. The drug pipeline includes ISA101 which consists of13 synthetic long peptides derived from the E6 and E7 oncogenic proteins of the HPV 16 virus for the treatment of human papillomavirus type 16 induced diseases, including cervical cancer, most anogenital premalignant and malignant lesions, and head and neck cancer, and others.
- Jul 2021Series B$30M
- Oct 2019Conventional Debt$22.1M
- Dec 2017Grant (prize money)$2M
- Jan 2013Series A$10.6M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Oncology & Cancer Therapeutics is moving in the Netherlands
A read on the academic research around Oncology & Cancer Therapeutics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 667 Netherlands-affiliated papers.
- Leiden University Medical Center107
- Oncode Institute103
- Amsterdam University Medical Centers87
- Radboud University Medical Center62
- Princess Máxima Center60
- Tumor microenvironment2→100
- Immunotherapy2→56
- Cancer research3→53
- Cancer immunotherapy1→27
- Stromal cell1→10
- Tumor microenvironment9→136
- Immune system6→108
- Cancer research9→99
- Immunotherapy8→88
- Cancer immunotherapy4→42
- Tumor microenvironment3→39
- Immune system3→31
- Immunotherapy6→33
- Cancer research5→24
- Cancer immunotherapy3→15
Where oncology is researched across Netherlands
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.